LUNG Stock Overview
A commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pulmonx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.83 |
| 52 Week High | US$14.84 |
| 52 Week Low | US$5.46 |
| Beta | 0.66 |
| 1 Month Change | -13.11% |
| 3 Month Change | -6.72% |
| 1 Year Change | -56.10% |
| 3 Year Change | -76.85% |
| 5 Year Change | n/a |
| Change since IPO | -85.17% |
Recent News & Updates
Recent updates
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%
Oct 22
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
Oct 02Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 15Pulmonx: Low Bar For Q2 Earnings
Jul 21Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch
Jun 07Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion
Apr 04Pulmonx: Revisiting Thesis Following Management Change
Mar 26Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?
Feb 23Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues
Aug 01Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically
Nov 08Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M
Aug 02Pulmonx: Interesting Technology But Struggling With Adoption
Jul 02These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts
Feb 28Shareholder Returns
| LUNG | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.8% | 1.3% | -0.8% |
| 1Y | -56.1% | 15.0% | 25.2% |
Return vs Industry: LUNG underperformed the US Medical Equipment industry which returned 16.6% over the past year.
Return vs Market: LUNG underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| LUNG volatility | |
|---|---|
| LUNG Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: LUNG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LUNG's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 279 | Steve Williamson | pulmonx.com |
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves.
Pulmonx Corporation Fundamentals Summary
| LUNG fundamental statistics | |
|---|---|
| Market cap | US$238.90m |
| Earnings (TTM) | -US$57.11m |
| Revenue (TTM) | US$79.30m |
2.9x
P/S Ratio-4.0x
P/E RatioIs LUNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUNG income statement (TTM) | |
|---|---|
| Revenue | US$79.30m |
| Cost of Revenue | US$20.49m |
| Gross Profit | US$58.81m |
| Other Expenses | US$115.92m |
| Earnings | -US$57.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | 74.16% |
| Net Profit Margin | -72.01% |
| Debt/Equity Ratio | 39.6% |
How did LUNG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 11:29 |
| End of Day Share Price | 2025/01/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pulmonx Corporation is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |